The importance of cooperation between urologist and oncologist in the treatment of castration-resistant prostate cancer
Abstract
Treatment of prostate cancer has become more complex in recent years, mainly due to the onset of new cytotoxic agents, antiandrogens and radiopharmaceuticals. The problem of sequential therapy will probably never be resolved, because there will always be new drugs involved in the therapeutic algorithms.
It is always necessary to take into account the patient's preferences, his performance status and comorbidities, and unfortunately also the possibilities of different departments. Groups of patients entering clinical trials are highly selected and do not reflect the reality of daily practice.
Multidisciplinary teams with participation of urologist, clinical and radiation oncologists and other specialities are thus of great importance. The consultation can select an appropriate treatment strategy for each patient individually, including the possibility to participate in clinical trials at the respective departments.
Abiraterone and enzalutamide will soon be approved for use in metastatic carcinoma before chemotherapy with indisputable advantage of a favourable side effects profile. Effective cytotoxic therapy will always be available in case of failure of these antiandrogens.